BB-Biont™

Healing the holobiont for a blemish-banned, smooth and healthy skin. 

BB-BIONT™ promotes the rebalance of the cutaneous microbiome. It helps avoid inflammation and pockmarks related to skin dysbiosis*. By rebalancing the skin’s microbiome, BB-BIONT™ clearly reduces inflammatory and post-inflammatory marks fading skin redness and evening the skin tone.

Application of a cream containing 1% BB-BIONT™ for 2 months on hemiface against placebo.

Use the slider to see the effect, simulation for illustration only.

2 independent clinical studies - Application of a cream containing 1% BB-BIONT™ for 2 months on hemiface against placebo.

1) 17 female and 1 male volunteers, mean age 32 [20-58]. Combination to oily skin with pockmarks and inflammatory marks.

2) 7 male and 23 female volunteers, mean age 24 [18-39]. Combination to oily skin with pockmarks, inflammatory marks and red or brown post-inflammatory marks.

A healthy skin microbiome:

Cutibacterium acnes after 1 month: -18.5%*/placebo
Staphylococcus epidermidis after 1 month: +15.4%**/placebo

Decrease of inflammatory marks 

Number of inflammatory marks: -22%¤¤/placebo. 90% respondents

Number of post-inflammatory marks: -17 %¤¤¤/placebo. 87% respondents.

« I have less inflammatory marks »: 74.1%$ ¤¤/T0.

Soothing of inflammatory marks:

Maximum skin redness: -7%¤¤/placebo. 89% respondents.

Heterogeneity in skin redness: -6.6% ¤¤¤/placebo. 72% respondents.

« I have less post inflammatory marks »: 83%¤¤/T0

Smoothing of pockmarks:

Volume of pockmarks (mm3): -18.9%¤/placebo, 100% respondents.

Skin roughness (mm3), -6.5%¤/placebo, 100% respondents.

Volume of inflammatory marks (mm3) : -34.3%¤¤/placebo, 94% respondents.

Significance:*p<0.067 vs placebo 
**non significant vs placebo 

¤p<0.01, ¤¤p<0.05, ¤¤¤p<0.08 vs placebo

$ p<0.05/T0